{"id":"W2763663030","doi":"10.1093/annonc/mdx440.034","title":"ARIEL3: A phase 3, randomised, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian carcinoma (OC)","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre; Ottawa Hospital; University Health Network","funders":"","keywords":"Medicine; Internal medicine; Clinical endpoint; BRCA mutation; Oncology; Placebo; Response Evaluation Criteria in Solid Tumors; PARP inhibitor; Progression-free survival; Population; Cancer; Gastroenterology; Ovarian cancer; Phases of clinical research; Chemotherapy; Clinical trial; Pathology; Genetics; Poly ADP ribose polymerase","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002144449,0.001989431,0.004967477,0.0007430766,0.0005831189,0.001275132,0.001551704,0.002766481,0.009001603],"category_scores_gemma":[0.002034078,0.001022584,0.002291045,0.0007074842,0.001830969,0.001582677,0.000504719,0.006206231,0.001970408],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007729425,"about_ca_system_score_gemma":0.001447106,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001394818,"about_ca_topic_score_gemma":0.003194191,"domain_scores_codex":[0.9992237,0.0003874735,0.00004798727,0.0001347483,0.00005322914,0.0001528664],"domain_scores_gemma":[0.9988344,0.0003778271,0.0002063196,0.0001135018,0.00005538003,0.0004125521],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9782637,0.006530931,0.0001548138,0.0004663839,0.000525828,0.00002177106,0.00003955702,0.0002152031,0.002427608,0.00008261439,0.0005518233,0.01071977],"study_design_scores_gemma":[0.943487,0.05469606,0.0005873982,0.00001414405,0.0001921698,0.00001812846,0.00001272311,0.0002470202,0.0003174299,0.00007892937,0.0003337931,0.00001524777],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9803354,0.005932839,0.001362426,0.001010831,0.001087975,0.005038942,0.001843943,0.0006283198,0.002759428],"genre_scores_gemma":[0.9788306,0.003378619,0.002624977,0.001620894,0.0007795634,0.005501484,0.00152942,0.0001242133,0.005610258],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.009001603,"threshold_uncertainty_score":0.0301134,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2027541194714337,"score_gpt":0.4880903689704883,"score_spread":0.2853362494990546,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}